Eli Lilly 2009 Annual Report Download - page 36

Download and view the complete annual report

Please find page 36 of the 2009 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 172

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172

Revenue
Our worldwide revenue for 2008 increased 9 percent, to $20.37 billion, driven primarily by growth of
Cymbalta, Cialis, Alimta, Humalog, and Gemzar. Worldwide sales volume increased 5 percent, while
foreign exchange rates contributed 3 percent, and selling prices contributed 2 percent. (Numbers do not
add due to rounding.) Revenue in the U.S. increased 8 percent, to $10.93 billion, driven primarily by
increased sales of Cymbalta, Humalog, Cialis, and Alimta. Revenue outside the U.S. increased 11 percent,
to $9.44 billion, driven primarily by revenue growth of Alimta, Cialis, Cymbalta, and Humalog.
The following table summarizes our revenue activity in 2008 compared with 2007:
Product U.S.
1
Outside U.S. Total
Year Ended
December 31, 2007
Total
Percent
Change
from 2007
Year Ended
December 31, 2008
(Dollars in millions)
Zyprexa . . .................... $ 2,202.5 $2,493.6 $ 4,696.1 $ 4,761.0 (1)
Cymbalta . .................... 2,253.8 443.3 2,697.1 2,102.9 28
Humalog . .................... 1,008.4 727.4 1,735.8 1,474.6 18
Gemzar . . .................... 734.8 985.0 1,719.8 1,592.4 8
Cialis
2
....................... 539.0 905.5 1,444.5 1,143.8 26
Alimta . . . .................... 561.9 592.8 1,154.7 854.0 35
Animal health products . . . ....... 537.3 556.0 1,093.3 995.8 10
Evista . . . .................... 700.5 375.1 1,075.6 1,090.7 (1)
Humulin . .................... 380.9 682.3 1,063.2 985.2 8
Forteo . . . .................... 489.9 288.8 778.7 709.3 10
Strattera . .................... 437.8 141.7 579.5 569.4 2
Other pharmaceutical products . . . . 664.8 1,222.7 1,887.5 1,895.6 —
Total net product sales . . ....... 10,511.6 9,414.2 19,925.8 18,174.7 10
Collaboration and other revenue
3
. . . 418.5 27.6 446.1 458.8 (3)
Total revenue . . . . . . . . . ....... $10,930.1 $9,441.8 $20,371.9 $18,633.5 9
1
U.S. revenue includes revenue in Puerto Rico.
2
Prior to the acquisition of ICOS in late January 2007, the Cialis revenue shown does not include net product sales in
the joint-venture territories of Lilly ICOS LLC (North America, excluding Puerto Rico, and Europe). Our share of the
joint-venture territory net product sales for January 2007, net of expenses and income taxes, is reported in other—net,
expense (income) in our consolidated statements of operations. Subsequent to the acquisition, all Cialis net product
sales are reported in our net revenue. Worldwide 2008 revenue for Cialis grew 19 percent from 2007 revenue of
$1.22 billion.
3
Collaboration and other revenue is primarily composed of 50 percent of Byetta’s gross margin in the U.S.
Zyprexa sales in the U.S. decreased 1 percent in 2008, driven by reduced demand, partially offset by higher
prices. Sales outside the U.S. decreased 1 percent, driven by decreased demand and, to a lesser extent,
lower prices, partially offset by the favorable impact of foreign exchange rates. Demand outside the
U.S. was unfavorably impacted by generic competition in Germany and Canada.
Sales of Cymbalta increased 23 percent in the U.S., driven by increased demand and, to a lesser extent,
higher prices. Sales outside the U.S. increased 66 percent, driven by increased demand and, to a lesser
extent, the favorable impact of foreign exchange rates and higher prices. Higher demand outside the
U.S. reflects increased demand in established markets as well as recent launches in new markets.
Sales of Humalog increased 14 percent in the U.S., driven by increased demand and higher prices. Sales
outside the U.S. increased 24 percent, driven by increased demand and, to a lesser extent, the favorable
impact of foreign exchange rates.
Sales of Gemzar increased 10 percent in the U.S., driven by increased demand and higher prices. Sales
outside the U.S. increased 7 percent, driven primarily by the favorable impact of foreign exchange rates
and, to a lesser extent, increased demand, partially offset by lower prices.
Sales of Cialis increased 27 percent in the U.S., driven by increased demand and higher prices. Sales
outside the U.S. increased 26 percent, driven by increased demand and, to a lesser extent, the favorable
impact of foreign exchange rates and higher prices. Total worldwide sales of Cialis increased 19 percent
24
FORM 10-K